Citation Impact

Citing Papers

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
2015 StandoutNobel
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
The Ensembl Variant Effect Predictor
2016 Standout
Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
2014
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation
2012
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
2016
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
2011
Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia
2012
Down syndrome and the complexity of genome dosage imbalance
2016
The molecular hallmarks of epigenetic control
2016 Standout
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients
2011
Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications
2015
Potential application ofIDH1andIDH2mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis
2012
Macrophages in immunoregulation and therapeutics
2023 Standout
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation
2012
Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways
2014 StandoutNobel
IDH mutations in acute myeloid leukemia
2012
Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML
2011
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
2015 StandoutNobel
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Translational implications of somatic genomics in acute myeloid leukaemia
2014
Molecular characterization ofde novoPhiladelphia chromosome-positive acute myeloid leukemia
2012
Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice
2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
2015
IDH1 mutation of gliomas with long-term survival analysis
2012
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Driver mutations of cancer epigenomes
2014
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
2012
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
2015
New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein
2010 StandoutNobel
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
2012
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
2014
Down syndrome
2020 Standout
Connections between TET proteins and aberrant DNA modification in cancer
2014
Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics
2015
The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
2013
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Recent developments in myelodysplastic syndromes
2014
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
2011
Acute Myeloid Leukemia
2015 Standout
ASXL1 mutations are frequent and prognostically detrimental in CSF3R‐mutated chronic neutrophilic leukemia
2015
Chronic Myelomonocytic Leukemia
2016
2016 US lymphoid malignancy statistics by World Health Organization subtypes
2016 Standout
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic‐French Consortium Study
2014
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance
2015
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
2013
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
1997 Standout
Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance
2018
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
2013
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
2013
Loss of TET proteins in regulatory T cells promotes abnormal proliferation, Foxp3 destabilization and IL-17 expression
2019 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia
2011
Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors
2016
Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
2012
New mutations and pathogenesis of myeloproliferative neoplasms
2011
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?
2014
Genomics of chronic neutrophilic leukemia
2016
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies
2021
IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F
2011
Does a Diagnosis of Myelogenous Leukemia Require 20% Marrow Myeloblasts, and Does <5% Marrow Myeloblasts Represent a Remission? The History and Ambiguity of Arbitrary Diagnostic Boundaries in the Understanding of Myelodysplasia
2013
Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
2011
Drug Resistance in Cancer: An Overview
2014 Standout
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2010
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
2014
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
2014

Works of Tamara Alpermann being referenced

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
2012
Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations
2011
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases
2012
Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
2013
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease
2013
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course
2012
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations
2013
Comparison of Cytogenetic Clonal Evolution Patterns following Allogeneic Hematopoietic Transplantation versus Conventional Treatment in Patients at Relapse of AML
2010
The role of different genetic subtypes of CEBPA mutated AML
2013
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells
2011
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia
2011
Landscape of TET2 mutations in acute myeloid leukemia
2011
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia
2011
Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
2012
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele
2011
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
2012
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
2013
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events
2011
Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia
2015
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity
2012
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis
2010
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
2010
Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies
2013
Rankless by CCL
2026